comparemela.com
  1. Home
  2. Live Updates
  3. Program Clinical Investigator - Breaking News

Latest Breaking News On - Program clinical investigator - Page 1 : comparemela.com

Boehringer Ingelheim: Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status

In a new sub-analysis of the landmark EMPEROR-Preserved Phase III trial, empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney

United statesStephan thalenFaiez zannadWaheed jamalStefanie molkenthinEli lillyJeff emmickGlobal business communicationsBoehringer ingelheimLilly allianceProgram clinical investigatorProduct developmentEuropean unionUniversity of lorraineAmerican society of nephrology kidney weekAmerican society

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.